Q2 2026 saw strong revenue and EPS growth, led by Dupixent, EYLEA HD, and Libtayo, with major pipeline and regulatory milestones achieved. Full reimbursement of the Sanofi development balance and robust launches in immunology and oncology set the stage for continued growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.